SEMI President Juana Cartero Gomez.
In Spain, 13.8 percent of people over the age of 18 have type 2 diabetes, ie more than 5 million people suffer from this disease. In addition, it is estimated that around 25,000 people die of diabetes in the country. One of the drugs used to treat these patients is semaglutide, similar to glucagon. Now, an investigation by the Diabetes, Obesity and Nutrition Working Group of the Spanish Society of Internal Medicine (SEMI), in which its president, Juana Cartero Gómez, participates, has found another beneficial effect of this drug. In this case, in patients with fatty liver of metabolic origin.
Semaglutide has come to the fore in recent months due to the use of the drug by some to lose weight, an effect that has been observed in obese type 2 diabetic patients using semaglutide as part of their treatment. In fact, the acquisition of the drug by people who do not suffer from the disease in order to lose weight has led to a worldwide supply shortage, including in Spain.
The SEMI group disclosed its results in the publication ‘Revista Clínica Española’. The aim of this study was “to assess the effect of subcutaneous semaglutide biomarkers of metabolic liver disease (MAFLD), that is, hepatic steatosis index (HSI) and fibrosis index-4 (FIB-4), at 24 weeks in outpatients cared for in internal medicine departments,” indicated the researchers.
The results show that Subcutaneous semaglutide “had beneficial effects on hepatic steatosis that went beyond glucose control”, indicates research. “The effects were mainly related to weight loss, reduction in biomarkers and improvement in insulin sensitivity,” the authors explain in the study. “For many patients, Early detection is essential to improve MAFLD outcomes and may allow the most effective therapeutic options to be selected,” he says.
method and result
The investigation “used patients from an in-use, multicenter, prospective, pre-post, and uncontrolled cohort registry that enrolled single and consecutive patients with type 2 diabetes treated with subcutaneous semaglutide.” for his part, Steatosis and fibrosis were determined by HSI. ,<30 खारिज, >36 Steatosis) Y FIB-4 ,<1.3 खारिज, > 2.67 fibrosis), respectively.
Total, Sample includes 213 patients, Of these, 46.9 percent were female and the average age was approximately 64 years (19 percent). On the other hand, the mean body mass index and basal weight were 36.1kg/m2 (8.4%) and 98kg (26.9%), respectively. “99.9 percent of patients had an HSI value suggestive of steatosis with a mean HSI of 47.9 (8.2). In addition, 10.8 percent presented with fibrosis (FIB-4 > 2.67) and 42.72 percent presented values in the intermediate ranges (FIB). -4 1.3–2.67), indicates probe.
after 24 weeks, There was a “significant reduction” of HSI and FIB-4 and was associated, primarily, with “decreases in body weight, triglyceride levels, insulin resistance (as estimated by the triglyceride-glucose ratio) and liver enzymes,” this study says.
In summary, in addition to helping type 2 diabetics control their disease, semaglutide also appears to be beneficial for patients with fatty liver of metabolic origin.
Although it may contain statements, data or notes from health institutions or professionals, the information contained in Redaccion Médica is edited and prepared by journalists. We advise the reader to consult a health professional with any health questions.